Miss Jenny Doyle, Dr Aaminah Haq and Dr Arshi Baig review the latest research in polynucleotide treatments in medical aesthetics
Globally, non-invasive aesthetic procedures accounted for more than £52 billion of revenue in 2023 and are increasing, with an annual growth rate of 15.4% from 2024 to 2030.1
Injectable treatments accounted for more than £32 billion of the market and have been forecasted to have the most significant growth by 2023.1 This rise has been largely driven by a need for treatments focusing on skin rejuvenation, steady advancements in biotechnology and an increasing inclination towards non-invasive procedures.2 The UK polynucleotides (PNs) market generated a revenue of more than £5 million and is forecasted to grow at a rate of 15% from 2025 to 2030.3
PNs are a regenerative aesthetic treatment, thought to be effective for multiple indications. They serve to address issues such as skin texture, elasticity and overall skin quality.2
Pharmacology and action
Deoxyribonucleotides (DNA) and ribonucleotides (RNA), found in all cells, allow organisms to reproduce. They are made of multiple ‘building blocks,’ termed nucleotides, chains of this monomer make up PNs. A nucleotide…
